Pirfenidone in Idiopathic Pulmonary Fibrosis: Mechanistic Insights, Clinical Evidence, and Future Therapeutic Horizons

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressively worsening interstitial lung disorder characterized by excessive deposition of extracellular matrix and irreversible decline in pulmonary function. Pirfenidone, a synthetic pyridone derivative, exhibits antifibrotic, anti-inflammatory, and antioxidant activities by modulating key mediators, including TGF-β, TNF-α, IL-1β, and NOX4. Evidence from both preclinical and clinical investigations indicates that pirfenidone effectively slows disease progression. Pharmacokinetic studies show that pirfenidone is rapidly absorbed and undergoes extensive hepatic metabolism, primarily via the CYP1A2 enzyme, leading to the formation of active metabolites. Phase III clinical trials, including the CAPACITY and ASCEND studies, have demonstrated that pirfenidone significantly reduces the rate of decline in forced vital capacity (FVC), improves progression-free survival, and provides overall survival benefits in pooled analyses. Although adverse effects such as gastrointestinal disturbances and photosensitivity are commonly reported, they are generally manageable with appropriate dose adjustments. Drug interaction studies highlight significant interactions with strong CYP1A2 inhibitors, including fluvoxamine, whereas no clinically relevant interactions have been observed with nintedanib. Emerging research focusing on inhaled delivery systems, combination therapies, and biomarker-driven strategies suggests expanded therapeutic potential. Overall, pirfenidone represents a well-established, evidence-based option for slowing disease progression in IPF and other fibrosing interstitial lung diseases.